Please assess the completion status of the following clinical trial:

Trial Title: A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Eye with recurrent Rb clinically defined as one or the combination of the following:~   * vitreous recurrence only~  * retinal / diffuse subretinal relapse only not amenable to focal treatment such as thermotherapy, cryotherapy or plaque~  * combined vitreous and retinal/diffuse subretinal relapse~2. Minimally required interval between study entry and time of the last treatment: 2 months (with a monthly follow-up), except for small retinal / subretinal tumors treated focally, not related to the current relapse~3. Photographic documentation of fundus at study entry~4. Registration into the study and start of treatment must occur no later than 14 days after diagnosis of recurrence~5. Mandatory ultrasound biomicroscopy (UBM) at 35 or 50 MHz in case of opaque media or insufficient pupillary dilatation for evaluation of the posterior chamber / pars plana~6. Age ≥3 months and \< 11 years (10.99)~7. Weight ≥5 kg (in case of IAC eligibility or sequential IVitC/IAC eligibility)~8. Possibility of follow-up until at least 2 years after end of current relapse treatment~9. Written informed consent by parents or legal representative before enrolment~Exclusion Criteria:~1. Relapse with any uveal involvement and/or anterior chamber involvement~2. Indication for another treatment option according to investigator's judgement~3. Clinical/MRI signs of extraocular disease, including metastatic disease~4. Inadequate organ function (in case of IAC or sequential IVitC / IAC eligibility):~   * absolute neutrophils count \<0.5 G/l~  * thrombocytes count \<100 G/l~  * creatinine above normal value for age~  * ALAT more than 2x above upper normal limit~  * bilirubin above upper normal limit~5. Other (simultaneous) malignancies~6. Contraindication or known hypersensitivity to study drugs~7. Severe concomitant diseases (e.g. immune deficiency syndrome)~8. Current or recent (within 30 days prior to date of written informed consent) treatment with another investigational drug or participation in another interventional clinical trial

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Treatment 1a (Type: ACTIVE_COMPARATOR): IVitC melphalan (randomized) in case of vitreous relapse only
- Treatment 1b (Type: EXPERIMENTAL): IVitC topotecan (randomized) in case of vitreous relapse only
- Treatment 2a (Type: ACTIVE_COMPARATOR): IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
- Treatment 2b (Type: EXPERIMENTAL): IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
- Treatment 2c (Type: NO_INTERVENTION): IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
- Treatment 3a (Type: NO_INTERVENTION): sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
- Treatment 3b (Type: NO_INTERVENTION): sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).